Short answer
Eton Pharmaceuticals, Inc. (ETON) filed an 8-K current report with the SEC on April 15, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement). Borrowing cost reduced to SOFR plus 6.55% from SOFR plus 6.75%.
Eton Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Borrowing cost reduced to SOFR plus 6.55% from SOFR plus 6.75%
- SOFR floor lowered to 2.75% from 5.0%, increasing rate sensitivity to lower SOFR
- Interest-only period extended through November 2026, preserving near-term liquidity
- Principal payment optional in May 2026 or deferred to November 2026
- December 2027 maturity unchanged with no amendment fees paid to SWK
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Eton Pharmaceuticals, Inc. 8-K filings
Get the next ETON 8-K as it lands
Follow ETON for push alerts, or ask the research agent what this filing means.